Research press release


Nature Communications

Cancer: Genetic marker for breast cancer survival



今回、Kamila Czeneたちは、免疫系と炎症に関係する遺伝子に影響を与える遺伝子多様体と乳がんの生存率との関連を調べた。今回の研究は、化学療法による治療を受けた多数のエストロゲン受容体陰性(ER)乳がん患者のグループについて行われ、免疫応答と乳房細胞の遊走と増殖に関与するケモカイン遺伝子CCL20において遺伝的マーカーが同定された。このマーカーがあると、乳がん特異的な死亡のリスクが高まる。


A genetic variant, in an immunity-related gene, that increases the risk of death from a specific type of breast cancer has been identified. The work, published in Nature Communications, highlights the importance of the immune system in breast cancer prognosis and sheds light on the genetic basis of the disease outcome after chemotherapy treatment.

Previous studies have shown that breast cancer survival rates correlate amongst family members and that the immune system may affect how patients respond to chemotherapy and influence their overall prognosis.

Kamila Czene and colleagues have looked for associations between genetic variants that exert an effect on genes involved in the immune system and inflammation, and breast cancer survival. Their research, on a large group of women with estrogen receptor negative (ER-) breast cancer who have undergone chemotherapy treatment, identified a genetic marker in CCL20-a chemokine gene involved in immune response and migration and proliferation of breast cells-that increases the risk of breast cancer-specific death.

This marker explains a small fraction of the variation associated with breast cancer survival, which suggests that much larger studies will be needed to fully understand the genetic basis of ER- breast cancer prognosis. This work provides an important step towards the identification of genes which could be targeted therapeutically to improve the prognosis of breast cancer patients undergoing treatment.

doi: 10.1038/ncomms5051

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。